Cargando…

2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population

BACKGROUND: High dose (HD) influenza vaccine has been shown to be more efficacious than standard dose (SD) vaccine in multiple randomized trials. HD is currently the most commonly used vaccine in US seniors (≥65 years of age). In this study, we evaluated the real-world relative vaccine effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Paudel, Misti, Mahmud, Salah, Buikema, Ami R, Korrer, Stephanie, Damon, Van Voorhis, Brekke, Lee, Chit, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809702/
http://dx.doi.org/10.1093/ofid/ofz360.2424
_version_ 1783462059580588032
author Paudel, Misti
Mahmud, Salah
Buikema, Ami R
Korrer, Stephanie
Damon, Van Voorhis
Brekke, Lee
Chit, Ayman
author_facet Paudel, Misti
Mahmud, Salah
Buikema, Ami R
Korrer, Stephanie
Damon, Van Voorhis
Brekke, Lee
Chit, Ayman
author_sort Paudel, Misti
collection PubMed
description BACKGROUND: High dose (HD) influenza vaccine has been shown to be more efficacious than standard dose (SD) vaccine in multiple randomized trials. HD is currently the most commonly used vaccine in US seniors (≥65 years of age). In this study, we evaluated the real-world relative vaccine effectiveness (rVE) of HD vs SD over 3 influenza seasons. METHODS: This study includes a cohort of Medicare fee-for-service enrollees during influenza seasons 2011–2012 to 2013–2014 who received either HD or SD at a pharmacy or an outpatient clinic. HD recipients were matched 1:1 to SD recipients based on location, date of vaccination, age, and gender. Fine-Gray subdistribution hazard models with competing risk of death were used to adjust for residual confounding. The study outcome of probable influenza was defined as any inpatient stay with an influenza diagnosis on the claim, or an outpatient medical encounter with a rapid influenza test/culture followed by an antiviral prescription. Analyses were stratified based on vaccination location (clinic vs pharmacy) as it is expected that physicians carrying both vaccines may prioritize HD to frailer patients, while pharmacists may not exercise clinical judgment. RESULTS: Over the influenza seasons 2011–2012, 2012/–2013, and 2013–2014, 1.6–2.2 million seniors were immunized at a pharmacy; and 3.3–3.5 million at a clinic. After matching, there were 535,598; 1,017,552; and 1,548,164 in the pharmacy cohort, and 821,662; 1,151,080; and 1,559,488 in the clinic cohort, across study years. The rVE over 2011/12, 2012/13, and 2013/14 during peak influenza circulation was 21.8% (95% CI: −5.9%, 42.3%), 14.8% (9.3%,19.9%), and 16.9% (9.2%, 23.9%), respectively, in the pharmacy cohort; and 16.5% (−5.9%, 34.2%), 15.1% (10.9%, 19.1%), 10.0% (2.9%, 16.6%), respectively, in the clinic cohort. CONCLUSION: HD was consistently associated with better protection against probable influenza events requiring outpatient or inpatient care. The slightly lower treatment effects observed in the outpatient clinic cohort could be a result of confounding by indication due to physicians triaging HD to frailer patients. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809702
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68097022019-10-28 2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population Paudel, Misti Mahmud, Salah Buikema, Ami R Korrer, Stephanie Damon, Van Voorhis Brekke, Lee Chit, Ayman Open Forum Infect Dis Abstracts BACKGROUND: High dose (HD) influenza vaccine has been shown to be more efficacious than standard dose (SD) vaccine in multiple randomized trials. HD is currently the most commonly used vaccine in US seniors (≥65 years of age). In this study, we evaluated the real-world relative vaccine effectiveness (rVE) of HD vs SD over 3 influenza seasons. METHODS: This study includes a cohort of Medicare fee-for-service enrollees during influenza seasons 2011–2012 to 2013–2014 who received either HD or SD at a pharmacy or an outpatient clinic. HD recipients were matched 1:1 to SD recipients based on location, date of vaccination, age, and gender. Fine-Gray subdistribution hazard models with competing risk of death were used to adjust for residual confounding. The study outcome of probable influenza was defined as any inpatient stay with an influenza diagnosis on the claim, or an outpatient medical encounter with a rapid influenza test/culture followed by an antiviral prescription. Analyses were stratified based on vaccination location (clinic vs pharmacy) as it is expected that physicians carrying both vaccines may prioritize HD to frailer patients, while pharmacists may not exercise clinical judgment. RESULTS: Over the influenza seasons 2011–2012, 2012/–2013, and 2013–2014, 1.6–2.2 million seniors were immunized at a pharmacy; and 3.3–3.5 million at a clinic. After matching, there were 535,598; 1,017,552; and 1,548,164 in the pharmacy cohort, and 821,662; 1,151,080; and 1,559,488 in the clinic cohort, across study years. The rVE over 2011/12, 2012/13, and 2013/14 during peak influenza circulation was 21.8% (95% CI: −5.9%, 42.3%), 14.8% (9.3%,19.9%), and 16.9% (9.2%, 23.9%), respectively, in the pharmacy cohort; and 16.5% (−5.9%, 34.2%), 15.1% (10.9%, 19.1%), 10.0% (2.9%, 16.6%), respectively, in the clinic cohort. CONCLUSION: HD was consistently associated with better protection against probable influenza events requiring outpatient or inpatient care. The slightly lower treatment effects observed in the outpatient clinic cohort could be a result of confounding by indication due to physicians triaging HD to frailer patients. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809702/ http://dx.doi.org/10.1093/ofid/ofz360.2424 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Paudel, Misti
Mahmud, Salah
Buikema, Ami R
Korrer, Stephanie
Damon, Van Voorhis
Brekke, Lee
Chit, Ayman
2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population
title 2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population
title_full 2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population
title_fullStr 2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population
title_full_unstemmed 2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population
title_short 2747. Relative Vaccine Efficacy of High-Dose vs. Standard Dose Influenza Vaccines in Preventing Probable Influenza in a US Medicare Fee-for-Service Population
title_sort 2747. relative vaccine efficacy of high-dose vs. standard dose influenza vaccines in preventing probable influenza in a us medicare fee-for-service population
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809702/
http://dx.doi.org/10.1093/ofid/ofz360.2424
work_keys_str_mv AT paudelmisti 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation
AT mahmudsalah 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation
AT buikemaamir 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation
AT korrerstephanie 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation
AT damonvanvoorhis 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation
AT brekkelee 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation
AT chitayman 2747relativevaccineefficacyofhighdosevsstandarddoseinfluenzavaccinesinpreventingprobableinfluenzainausmedicarefeeforservicepopulation